Sahajanand Medical Technologies Ltd
SMT Sahajanand Medical Technologies Ltd
BSE IPO
Bidding dates15 Oct 2026 - 19 Oct 2026
Price range₹327 - ₹344
Min. investment₹14,792
Issue size475.48 Cr
Lot size43 Shares
IPO Timeline
Start date
15 Oct 2026
End date
19 Oct 2026
Allotment date
21 Oct 2026
Refund initiation
22 Oct 2026
Share credit
22 Oct 2026
Deactivate mandate
23 Oct 2026
About company
Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs). The Company focuses on research and development, precision manufacturing and clinically supported product innovation. Its flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology.
The Company operates three manufacturing facilities, two in India and one in Thailand, supported by two R&D centres in India and Thailand. As of June 30, 2026, it had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India. Its products were marketed in 77 countries in Fiscal 2026, through direct, hybrid and distributor-led models, with established market presence in India, Europe and other international markets.
The Company reported revenue from operations of ?12,105.04 million in Fiscal 2026, compared with ?10,248.79 million in Fiscal 2025 and ?9,016.04 million in Fiscal 2024.
As of June 30, 2026, it had 1,605 full-time employees, 31 consultants and 707 contract-based employees.
Founded in 2001
Managing director Bhargav Dhirajlal Kotadia
Parent organisation Sahajanand Medical Technologies IPO
Invest in Sahajanand Medical Technologies Ltd now!
Strengths and Risks
Strengths
The company markets its specialized medical portfolios across nearly 70–80 countries. International operations have scaled consistently, accounting for a major share of total revenues.
Operates dedicated R&D facilities in India and Thailand, holding over 100 granted global patents and a continuous pipeline of patent applications.
Operates certified manufacturing units across Surat, Hyderabad, and Thailand, holding major quality management certifications (ISO 13485, CDSCO, CE approvals, etc.).
Risks
The IPO structure comprises 100% Offer for Sale (OFS) shares (aggregating around Rs 475.48 crore). This means zero fresh capital flows into the company's balance sheet; the proceeds go entirely to exiting promoters and early private equity/investors.
The company’s financial performance is closely tethered to the success and market acceptance of its core product lines (specifically flagship stents like the Supraflex series). Any adverse clinical developments or regulatory shifts regarding these lines heavily impact top-line growth.
As a manufacturer of Class III / high-risk medical devices, SMT is subject to strict domestic and international regulatory approvals. Delays in license renewals, stringent price controls, or healthcare reimbursement policy caps across target countries can compress margins.
Explore our feature-rich web trading platform
Get the link to download the App
